KR20230080448A - 유전성 출혈성 모세혈관확장증의 치료에 사용하기 위한 알로스테릭 akt 저해제 - Google Patents

유전성 출혈성 모세혈관확장증의 치료에 사용하기 위한 알로스테릭 akt 저해제 Download PDF

Info

Publication number
KR20230080448A
KR20230080448A KR1020237014688A KR20237014688A KR20230080448A KR 20230080448 A KR20230080448 A KR 20230080448A KR 1020237014688 A KR1020237014688 A KR 1020237014688A KR 20237014688 A KR20237014688 A KR 20237014688A KR 20230080448 A KR20230080448 A KR 20230080448A
Authority
KR
South Korea
Prior art keywords
compound
hht
subject
treatment
telangiectasia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237014688A
Other languages
English (en)
Korean (ko)
Inventor
다미앙 피카르
피에르 생-메자르
Original Assignee
바데리스 쎄라퓨틱스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바데리스 쎄라퓨틱스 아게 filed Critical 바데리스 쎄라퓨틱스 아게
Publication of KR20230080448A publication Critical patent/KR20230080448A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020237014688A 2020-09-30 2021-09-29 유전성 출혈성 모세혈관확장증의 치료에 사용하기 위한 알로스테릭 akt 저해제 Pending KR20230080448A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2015536.2 2020-09-30
GB2015536.2A GB2600384A (en) 2020-09-30 2020-09-30 Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
PCT/EP2021/076811 WO2022069552A1 (en) 2020-09-30 2021-09-29 Allosteric akt inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Publications (1)

Publication Number Publication Date
KR20230080448A true KR20230080448A (ko) 2023-06-07

Family

ID=73197201

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237014688A Pending KR20230080448A (ko) 2020-09-30 2021-09-29 유전성 출혈성 모세혈관확장증의 치료에 사용하기 위한 알로스테릭 akt 저해제

Country Status (13)

Country Link
US (1) US12466839B2 (https=)
EP (1) EP4221713A1 (https=)
JP (1) JP2023543993A (https=)
KR (1) KR20230080448A (https=)
CN (1) CN116419924A (https=)
AU (1) AU2021352108B2 (https=)
BR (1) BR112023004885A2 (https=)
CA (1) CA3192433A1 (https=)
CL (1) CL2023000926A1 (https=)
GB (1) GB2600384A (https=)
IL (1) IL301466A (https=)
MX (1) MX2023002996A (https=)
WO (1) WO2022069552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2026038045A1 (en) 2024-08-15 2026-02-19 Almac Discovery Limited Crystalline forms of 6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl)phenyl)-1-ethyl-7-phenyl-1h-pyrido[2,3-b][1,4]oxazin-2(3h)-one salts and free base

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI301760B (en) 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1898903B8 (en) 2005-06-10 2013-05-15 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
JP2010512312A (ja) 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
JP2011522048A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
US8536193B2 (en) 2008-06-03 2013-09-17 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
EP2116237A1 (en) 2008-08-05 2009-11-11 Polichem SA Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
EA201101186A1 (ru) 2009-02-13 2012-04-30 Байер Фарма Акциенгезельшафт Конденсированные пиримидины
GB0922589D0 (en) 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
EP3294314A4 (en) 2015-05-15 2019-01-16 Memorial Sloan Kettering Cancer Center USE OF PHOPHOINOSITIDE-3-KINASE INHIBITORS FOR THE TREATMENT OF VASCULAR DISEASES
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Also Published As

Publication number Publication date
US20240092801A1 (en) 2024-03-21
AU2021352108A1 (en) 2023-05-11
CN116419924A (zh) 2023-07-11
GB2600384A (en) 2022-05-04
WO2022069552A1 (en) 2022-04-07
CL2023000926A1 (es) 2023-11-03
EP4221713A1 (en) 2023-08-09
JP2023543993A (ja) 2023-10-19
MX2023002996A (es) 2023-05-03
CA3192433A1 (en) 2022-04-07
GB202015536D0 (en) 2020-11-11
AU2021352108B2 (en) 2026-04-02
US12466839B2 (en) 2025-11-11
BR112023004885A2 (pt) 2023-04-18
IL301466A (en) 2023-05-01
AU2021352108A9 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
KR101443651B1 (ko) Ｆｌｔ-3 키나제의 억제 방법
KR101538822B1 (ko) 혈관 내피 성장 인자 수용체에 대한 특이적 억제제
Hong et al. Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy
US7875603B2 (en) Specific inhibitors for vascular endothelial growth factor receptors
US20190300511A1 (en) 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
EP2651403B1 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
US12071438B2 (en) Crystal forms of an ALK2 inhibitor
JP2006502165A (ja) ピラゾロピリジンならびにその作製および使用方法
TW201629059A (zh) 二氫吲哚啉酮衍生物
KR20230080448A (ko) 유전성 출혈성 모세혈관확장증의 치료에 사용하기 위한 알로스테릭 akt 저해제
JP2017516860A (ja) Ａｒｆ６阻害剤並びにそれらの合成方法及び使用
AU2017281980B2 (en) Wnt inhibitors for use in the treatment of fibrosis
JP5788320B2 (ja) イソｑｃ阻害剤の使用
WO2022014707A1 (ja) 眼疾患の治療薬としてのｔｒｐｖ４阻害薬
JP2021516225A (ja) イミダゾジアゼピンジオン及びその使用方法
EA049324B1 (ru) Аллостерические ингибиторы akt для применения в лечении наследственной геморрагической телеангиэктазии
CN104788423B (zh) 一种新的囊性纤维化跨膜传导调节因子抑制剂
JP2022500478A (ja) 新規な（イソプロピル−トリアゾリル）ピリジニル置換されたベンゾオキサジノン又はベンゾチアジノン誘導体及びその用途
WO2015173656A1 (en) Carboxamide derivatives
HK40074977A (en) Carboxylic acid aromatic amides as antagonists of bradykinin b1 receptor
HK1254606B (zh) 手性二芳基大环及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902